- Home
- CULP vs KLRS Comparison
CULP vs KLRS Comparison
Compare CULP & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CULP
- KLRS
- Stock Information
- Founded
- CULP 1972
- KLRS 2019
- Country
- CULP United States
- KLRS United States
- Employees
- CULP N/A
- KLRS N/A
- Industry
- CULP Textiles
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CULP Consumer Discretionary
- KLRS Health Care
- Exchange
- CULP Nasdaq
- KLRS Nasdaq
- Market Cap
- CULP 54.5M
- KLRS 46.0M
- IPO Year
- CULP N/A
- KLRS N/A
- Fundamental
- Price
- CULP $4.49
- KLRS $4.44
- Analyst Decision
- CULP
- KLRS Strong Buy
- Analyst Count
- CULP 0
- KLRS 2
- Target Price
- CULP N/A
- KLRS $23.00
- AVG Volume (30 Days)
- CULP 18.7K
- KLRS 726.0K
- Earning Date
- CULP 09-10-2025
- KLRS 11-15-2025
- Dividend Yield
- CULP N/A
- KLRS N/A
- EPS Growth
- CULP N/A
- KLRS N/A
- EPS
- CULP N/A
- KLRS N/A
- Revenue
- CULP $207,391,000.00
- KLRS N/A
- Revenue This Year
- CULP $2.41
- KLRS N/A
- Revenue Next Year
- CULP $3.46
- KLRS N/A
- P/E Ratio
- CULP N/A
- KLRS N/A
- Revenue Growth
- CULP N/A
- KLRS N/A
- 52 Week Low
- CULP $3.42
- KLRS $2.14
- 52 Week High
- CULP $6.85
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- CULP 55.13
- KLRS 59.74
- Support Level
- CULP $4.45
- KLRS $3.49
- Resistance Level
- CULP $4.80
- KLRS $4.90
- Average True Range (ATR)
- CULP 0.20
- KLRS 0.81
- MACD
- CULP 0.03
- KLRS 0.01
- Stochastic Oscillator
- CULP 56.94
- KLRS 32.54
About CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.